Compound 451238
Alternative Names: Compound 451238Latest Information Update: 02 Oct 2021
At a glance
- Originator Royal Marsden NHS Foundation Trust
- Developer Merck KGaA; Royal Marsden NHS Foundation Trust
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Soft tissue sarcoma
Most Recent Events
- 08 Apr 2020 Compound 451238 is still in phase I/II trials for Soft tissue sarcoma (Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in United Kingdom (unspecified route) (NCT03602833)
- 05 Nov 2018 Phase-I/II clinical trials in Soft tissue sarcoma (Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in United Kingdom (unspecified route) (NCT03602833)
- 29 Jul 2018 Royal Marsden NHS Foundation Trust and Merck KGaA plan a phase I/II trial for Soft-tissue sarcoma (Combination therapy) in United Kingdom (NCT03602833) (EudraCT2017-001316-11)